Simponi (Golimumab)

Simponi is manufactured in the United States and shipped in cold chain packaging from our pharmacy by courier in India.

Simponi (golimumab) is called a TNF blocker which blocks the action of TNF alfa.  TNF alfa is part of the inflammatory process thus blocking it can reduce inflammation for people with inflammatory diseases. Simponi is for adults with inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and ulcerative colitis.

Information about Simponi (Golimumab)

Simponi is a biologic medication containing golimumab, which is a monoclonal antibody used to treat autoimmune diseases. It works by targeting and inhibiting tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine involved in various inflammatory conditions. By blocking TNF-α, Simponi helps reduce inflammation and symptoms associated with conditions like rheumatoid arthritis, ulcerative colitis, and ankylosing spondylitis.

Product Highlights

• Simponi is used to treat moderate to severe rheumatoid arthritis in adults, often in combination with methotrexate, to reduce symptoms and prevent joint damage.
• It is used to treat moderately to severely active ulcerative colitis in adults who have not responded well to conventional therapies.
• Simponi is used to treat ankylosing spondylitis, a form of arthritis that primarily affects the spine and can cause pain and stiffness.
• It is also approved for treating psoriatic arthritis, a condition that causes joint inflammation and skin symptoms.
• Although not primarily indicated, golimumab has been studied for use in managing Crohn's disease in certain patients.

Key Ingredient

• Golimumab

Key Benefits

• Simponi is effective in treating several autoimmune diseases, including rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis.
• It provides long-term relief by reducing inflammation and preventing joint damage or disease progression.
• Once the initial loading dose is given, Simponi is administered once a month, which is less frequent than some other biologic treatments.
• By reducing the symptoms of inflammation, Simponi helps improve overall mobility, reduce pain, and improve the quality of life for patients with chronic autoimmune conditions.

Direction of Use

• Simponi is administered as a subcutaneous injection, usually in the thigh or abdomen. 
• The usual dosing schedule starts with a loading dose of 200 mg, followed by maintenance doses of 100 mg once a month.
• After the initial loading dose, patients can be trained to administer the injection themselves at home, though this should be done under the guidance of a healthcare provider.
• Patients receiving Simponi should be monitored regularly for side effects and to evaluate the drug’s effectiveness.

Safety Concerns

• Because Simponi suppresses the immune system, it can increase the risk of serious infections, including tuberculosis (TB), bacterial infections, fungal infections, and viral infections like hepatitis B. TB screening should be done before starting treatment.
• TNF inhibitors like Simponi may increase the risk of certain cancers, including lymphoma and skin cancer.
• Golimumab may worsen heart failure in some individuals. Patients with heart failure should be carefully monitored. 
• Simponi can cause liver damage in rare cases. Regular liver function tests are recommended.
• In some patients, serious allergic reactions, including anaphylaxis, may occur. Patients should be monitored for signs of allergic reactions, especially during the first dose.
• Rare blood disorders, such as low blood cell counts, may occur. Blood tests should be done regularly to check for this.
• There have been reports of nervous system disorders, including multiple sclerosis and seizures, in patients receiving TNF inhibitors.

Avoid Simponi (Golimumab) If

• Simponi should be avoided in patients with active infections, including tuberculosis, bacterial, viral, or fungal infections, unless the infection is appropriately treated.
• Patients who have had a severe allergic reaction to golimumab or any of its components should not use Simponi.
• Simponi is contraindicated in patients with severe heart failure (New York Heart Association Class IV).
• Patients with severe liver impairment should avoid Simponi, as it can worsen liver function.
• Simponi should only be used during pregnancy or breastfeeding if the potential benefits surpass the risks. It is recommended to consult with a healthcare provider before starting the medication in these cases.

This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.